Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “LAUNDRIES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 721 records · Page 40Linked to original sources
PubMed1975

Allergic contact dermatitis to underwear elastic. Chemically transformed by laundry bleach.

Six subjects, allergic to the elastic in their undergarments, were patch test-negative to the rubber components and new elastic from the suppliers. However, washing the rubber with sodium hypochlorite gave the subjects allergic responses due to the effect of bleach on the rubber accelerator, zinc dibenzyldithiocarbamate (ZDC). To identify the allergen, ZDC was reacted with the sodium hypochlorite, and the resultant gum was extracted with diethyl ether. Eight compounds were identified in the reaction mixture by gas chromatography-mass spectrometry. The individual components were tested on volunteers after sensitization to the reaction mixture was produced in 14 of 25 volunteers. One component, N,N-dibenzylcarbamyl chloride produced an allergic response in each sensitized volunteer.

Allergens↗
PubMed2000

[From laundry product to cancer drug--history of a drug class].

BACKGROUND: In recent years, the management of tumor-induced bone lesions has been fundamentally changed by the therapeutic class of the bisphosphonates. TUMOR-INDUCED HYPERCALCEMIA (TIH): This was the first oncological entity to be treated with bisphosphonates. Because of the impaired renal function that always accompanies TIH, bisphosphonates must be infused sufficiently diluted and over a period of 2 to 4 h in this indication. The success rate (normalisation of serum calcium levels) with pamidronate is > 90%. TUMOR-INDUCED OSTEOLYSIS (TIO): Intravenously administered bisphosphonates like pamidronate do not only significantly reduce the rate of complications from TIO, both in breast cancer and multiple myeloma, but they also frequently lead to a remission in bone (sclerosis of the lesion). For the modern amino-bisphosphonates a direct anti-tumoral effect could be shown, too. NEW DEVELOPMENTS: New bisphosphonates of the 3rd generation are under development. Zoledronat, a new chemical entity from Novartis, is currently the most potent bisphosphonate. Clinical studies have shown that zoledronate is significantly more effective than pamidronate in the treatment of HCM. CONCLUSION: Bisphosphonates are today an important part of the standard therapy of tumor-induced bone diseases. Due to their direct anti-tumoral effects, the modern drugs of this class play an increasing role also in the prevention of bone metastases.

Bone Neoplasms↗